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Melanoma is a potentially lethal type of skin cancer and regarded to be the third most 
common type of skin cancer. Although melanoma is not as common as basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC), it is more likely to metastasize 
than BCC and SCC. Interestingly, the incidence of melanoma continues to go up 
(expected 2% in 2020), but the deaths continue to decrease (-5.3% in 2020) due to 
improvements in detection and treatment. The treatment of melanoma depends on several 
aspects but most importantly the tumor's stage and the location. In the early stages, 
melanoma can be removed via surgical operation, but in the late stages, melanoma 
usually treated with radiation or targeted therapy. Many factors predict the development 
of melanoma like skin pigmentation, age, sun exposure (UV light), and genetic 
mutations. The p53 protein initiates apoptosis and cell cycle arrest in response to stresses 
that cause DNA damage like UV light. However, mutant p53 is frequently detected in 
numerous cancers, including melanoma. MDM2 and MDM4 negatively regulate p53. 
Notably, a study indicates that MDM4 is overexpressed in 65% of melanoma. Therefore, 
there is a strong rationale to target MDM4 therapeutically, but MDM4 has several spliced 
variants, and some variants were detected in human and murine cancers. Yet, no studies 
have assessed the relative levels of MDM4 splice variants in melanoma. Therefore, in 
this study, we aimed to identify which variants are expressed in melanoma. We collected 
clinical specimens and designed specific primers for each isoform by RT-PCR. We 
observed no expression of MDM4-211 in either malignant and nevi samples. MDM4-
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Alt1 was present only once in nevi samples. Other variants were similarly present in nevi 
and malignant samples, but MDM4-A was the most commonly expressed variant in 
melanoma samples. Data were also collected and analyzed from publicly available 
databases to examine MDM4 expression in normal skin and melanoma and the survival 
data associated with each isoform. The results also showed that MDM4-A is the most 
common isoform expressed in melanoma. In conclusion, our data suggest that aberrant 
splicing of MDM4 occurs early in carcinogenesis of melanoma, MDM4 is more 
frequently amplified than its family member MDM2, that MDM4 has more change in 
splicing than what is observed in MDM2, and supports the view that MDM4-A is an 
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A. Human Melanomas 
 
Melanoma is considered to be the third most widespread sort of skin carcinoma and is 
responsible for many of the skin cancers fatalities in the United States (Jemal, A et al., 2011) 
(Jemal, A et al., 2013) (Gruber SB et al., 2006) (The US Department of Health and Human 
Services, 2014).  Worldwide, the rate of melanoma occurrence has been growing 
dramatically more than any other malignancy. (Ali, Z et al., 2013). Melanoma is the fifth 
most common cancer among males and the seventh most common cancer among females 
(Reed, K. B et al., 2012). A study performed on evaluating the gender role in the survival of 
melanoma patients showed that female patients exhibit notably more prolonged survival than 
male patients (Morgese, F et al., 2015). According to the U.S. Department of Health and 
Human Services, melanoma incidence rates have been rising over the past 40 years in the 
United States (Tripp, M. K et al., 2016). Over 63,000 people in the U.S. have melanoma, 
leading to the death of approximately 9,000 people annually (U.S. Cancer Statistics Working 
Group, 2014) (NPCR and SEER, 2011) (The US Department of Health and Human Services, 
2014). The occurrence of malignant melanoma in non-white Americans is significantly lower 
than in white Americans. According to American Cancer Society, the likelihood of 
developing melanoma is nearly 2.6% (1 in 38) for white Americans compared to 0.1% (1 in 
1,000) for African Americans, and 0.6% (1 in 167) for Latino Americans. However, 
according to the National Cancer Institute, melanoma incidence in recent years have dropped 
substantially, nearly 5.3% yearly due to advancements in melanoma therapy. Melanoma 
occurs in different forms such as nodular melanoma, lentigo maligna melanoma and acral 
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lentiginous melanoma, but the typical form is cutaneous malignant Melanoma (CMM) in the 
white American population (Hayward N. K., 1996) (Palmer, J. S et al., 2000). Exposure to 
sunlight, fair skin, dysplastic nevi syndrome, and a family history of melanoma are 
significant risk factors for melanoma formation (Markovic, S. N et al., 2007). Additionally, 
several host factors influence the risk of developing melanoma, including genetic 
susceptibility, family history, and the number of congenital melanocytic nevi (Bauer, J., & 
Garbe, C., 2003) (Hawkes, J. E et al., 2016) (reviewed in Leonardi, G. C E et al., 2018).  The 
interactions between environmental and genetic risk factors that drive carcinogenesis are 
presently the area of interest of ongoing research. Avoiding sunlight and improved 
monitoring vulnerable of patients have the potential to lessen the burden of melanoma in the 
human population.  
B. The Molecular Biology of Melanoma  
 Though over 95% of tumors are seen in the skin, melanoma is not solely a skin cancer 
(Markovic, S. N et al., 2007). Melanoma can occur in multiple sites, such as the eye, mucosal 
tissue, GI tract, urogenital system, the brain, and lymph nodes. The role of melanocytes is 
well-studied and described in the skin. In the basal layer of the dermis, melanocytes form 
intimate connections with keratinocytes, through slender dendritic processes that shuttle of 
melanosomes to keratinocytes (Markovic, S. N et al., 2007). Melanoma development is the 
consequence of genetic alterations and tumor microenvironmental modifications, 
distinguished by the high expression of proteins capable of promoting tumor infiltration and 
invasion (Chiriboga, L et al., 2016) (Guarneri, C, L et al., 2017) (Reviewed in  Leonardi, G. 
C E et al., 2018). Interestingly, melanomas have one of the most significant levels of somatic 
genetic modifications in human tumors (Vogelstein, B et al., 2013) (Akbani R et al., 2015) 
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(Reviewed in Leonardi, G. C E et al., 2018). The prevalent somatic mutations in sunlight-
exposed skin in melanoma impact genes that regulate vital biological processes, such as 
proliferation (NRAS, BRAF, and NF1), metabolism and growth (PTEN and KIT), resistance 
to cell-programmed death  (TP53), cell cycle arrest (CDKN2A) and replicative life cycle 
(TERT) (Hodis, E et al., 2012) (Krauthammer, M et al., 2012) (Reviewed in  Leonardi, G. C 
E et al., 2018). These genomic changes commonly trigger the abnormal activation of two 
major signaling pathways in melanomas: the MAPK pathway and the PI3K pathway 
(Chappell, W. H et al., 2011) (Reviewed in Leonardi, G. C E et al., 2018). The negative 
regulation of the MAPK pathway is observed in numerous human carcinomas, including 
melanoma, which commonly occurs due to genetic alterations in the RAS family genes and 
B-RAF gene or other genes involved in the MAPK pathway (Davies, H  et al., 2002) 
(Mercer, K. E  et al., 2003) (Maldonado, J. L et al., 2003) (N. Dhomen, R., 2009) (Inamdar, 
G. S et al., 2010). Genetic changes in the RAF/MEK/ERK pathway influence cell growth, 
metastasis, and viability of melanoma cells in vitro. Thus, it is apparent that B-Raf mutation 
plays a central role in melanoma biology. BRAF is a serine/threonine-protein kinase with 
downstream signaling impacts on RTKs and RAS protein (Rother & Jones, 2009) (Staibano, 
S et al., 2011). The frequent occurrence of B-Raf genetic mutations in melanoma and nevi is 
interesting, being observed in about 30% to 80% of melanoma cases (Thomas et al., 2006) 
(Staibano, S et al., 2011). Surprisingly, BRAF mutations in melanoma cells have a different 
mutational spectrum than in other cancers, potentially due to the exposure to UV light 
(Thomas et al., 2006) (Staibano, S et al., 2011). Amongst these single mutations, the most 
frequent is V600E (valine replacing glutamic acid), which makes up more than 90% of total 
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BRAF mutations. The mutation of BRAFV600E is caused by UV exposure (Meyle & 
Guldberg, 2009) (Balazs, M et al., 2011). 
C. Current Treatment of Cutaneous Melanoma 
Cutaneous melanoma has four main subtypes:  superficial spreading melanoma accounting 
for nearly 70% of all melanomas, nodular melanoma accounting for 15–30% of all 
melanomas, lentigo maligna (LM), and acral lentiginous (Evans, M. S et al., 2013). Most 
melanomas appear as abnormal superficial swellings on the skin and may continue for a long 
time in a phase known as the radial growth phase. In this phase, the melanomas are mostly 
curable by surgery alone. In the vertical growth phase, which is considered a step toward 
metastasis, measuring the thickness of the tumor is the most common method to predict 
melanoma prognosis (Evans, M. S et al., 2013). Surgery is still regarded as the main therapy 
of any primary melanoma site, and earlier detection with appropriate surgical intervention 
presently provides a possible cure for melanoma patients at early stages. The purpose of 
surgical treatment is to locally control the tumor and to secure the patient's long-term 
survival without functional limitation and disability. At present, effective surgery relies on 
accurate melanoma staging (Rutkowski, P et al., 2010). According to the Skin Cancer 
Foundation, if the thickness of melanoma measures 0.8 mm or larger or has other 
characteristics like ulcers that cause it to be very likely increase the likelihood reaching the 
lymph nodes, a sentinel lymph node biopsy may be done contemporaneously with surgery. 
The use of sentinel lymph node biopsy (SLNB) in melanoma treatment is well established. In 
stage I and II melanoma, experiments have confirmed that elective lymph node dissection has 
no survival advantage over nodal observation, but SLNB correlates with survival rate in 
patients with intermediate thickness melanoma (1–4 mm) positively compared to nodal 
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observation (Balch, C. M et al., 2000) (Wernick, B. D., 2017). As for advanced melanoma, 
immunotherapeutic treatments are being examined to develop targeted therapies for patients 
(Kanehisa, M et al., 2017) (Rodríguez-Cerdeira, C., 2017). Melanoma metastasis is 
commonly linked with critical immune tolerance, which is described in part by the weak 
immunogenicity of melanoma antigens (Ascierto, P. A. et al., 2014) (Rodríguez-Cerdeira, C., 
2017). The Cancer Genome Atlas (TCGA) characterizes four subtypes TCGA divided 
melanoma based on the mutational profile of the BRAF, RAS, and NF1 genes. Hence, drugs 
targeting these genes have been considered as melanoma candidate treatments. Nevertheless, 
resistance to BRAF inhibitor drugs contributes to treatment failure. The mechanisms for drug 
resistance have been attributed to mutations in different genes (Rajkumar, S et al., 2016) 
(Johnson, D. B et al., 2015) (Rodríguez-Cerdeira, C., 2017). Therefore, a promising 
therapeutic strategy for melanoma patients is multimodality therapy to inhibit several 
pathways concurrently, such as the MAPK (using trametinib and cobemetinib) and the BRAF 
(using vemurafenib or dabrafenib) pathways, which gives a positive effect in the vast 
majority of melanoma patients (Johnson, D. B et al., 2014) (Rodríguez-Cerdeira, C., 2017). 
Immunotherapy is a significant advantage in the treatment of advanced stages of melanoma. 
Generally, immunotherapy is defined as the utilization of immune cells to eradicate cancer 
cells by stimulating the patient's intrinsic immune system. Immunotherapy can be classified 
into several groups such as cytokines (IL-2, IFN α-2b), immune checkpoint blockade (PD-1, 
CTLA-4), oncolytic virus, and by transferring activated T-cells to the tumor-infiltrating 
lymphocytes (TILs) (TCR-engineered T cell, ACT, and CAR-T) (Yu, C et al., 2019). 
Recently, immune checkpoint inhibitors have been utilized for the development of 
immunotherapy. For metastatic melanoma, ipilimumab, nivolumab, and pembrolizumab have 
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been approved and used for blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
and programmed death-1 (PD-1). However, immunotherapies showed a limited impact on 
melanoma patients, and for some, resulted in severe immune-related adverse events (irAEs) 
(Kitano, S et al., 2018). 
D. Role of p53 in melanoma 
A tumor suppressor protein that controls the cellular life cycle, DNA replication, and 
apoptosis during tumor development is called p53 (Luo et al., 2017) (Kanapathipillai M. 
2018). If p53 is mutated, it loses its function, leading to abnormal cell growth 
(Kanapathipillai M. 2018). Most human cancers carry a mutated p53 gene, implying that p53 
is a critical tumor suppressor gene (Donehower, L. A et al., 1992) (Ozaki, T., & Nakagawara, 
A., 2011). The p53 family of proteins share a similar structure with three domains: the 
sequence-specific DNA-binding domain, the transcriptional activation domain, and the 
tetramerization domain (Reviewed by Harms, K et al., 2006). The majority of TP53 
mutations occurred in the p53 DNA binding domain. In healthy cells, p53 protein is kept at 
low levels via the regulation of several regulators like MDM2, a p53 ubiquitin ligase protein 
that capable of initiating degradation (Haupt et al., 1997) (Honda et al., 1997) (Kubbutat et 
al., 1997) (Kastenhuber, E. R., & Lowe, S. W. 2017). Nevertheless, in response to various 
biological stresses, p53 is stabilized, including DNA damage and replication stress produced 
by deregulated oncogenes. Mechanisms that drive p53 activation can be stimulus-dependent: 
for instance, DNA damage increases p53 phosphorylation, preventing MDM2-mediated 
degradation (Shieh, S. Y et al., 1997) (Kastenhuber, E. R., & Lowe, S. W., 2017). Promoting 
cell cycle arrest and apoptosis are the best understood functions of p53 protein. Indeed, 
fundamental studies conducted in the 90s revealed that p53 is essential for inducing the G1 
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phase checkpoint in response to reversible DNA damage (Kastan et al., 1991) (Kastenhuber, 
E. R., & Lowe, S. W. 2017). In cutaneous malignant melanoma, 12-19% of cases exhibited 
TP53 somatic mutations (Berger, M. F et al., 2012) (Hugo, W et al., 2016) (Hajkova, N et al., 
2018). However, nearly 90% of cutaneous melanoma cases exhibited inactivation of wild-
type p53, with approximately 10% of these cases having inactivating point mutations 
(Hocker, T., & Tsao, H. 2007) (Box, N. F et al., 2014). The biology that lies underneath the 
p53 regulation in melanoma cells and melanocytes must be understood to get a complete 
view of the potential activation of wild type p53 as a form of therapy. Many studies have 
shown that melanoma cells are moderately resistant to apoptosis induced by p53. 
Furthermore, the expression of p53 protein is induced less effectively in response to UV 
exposure in melanocytes than in other skin cells like keratinocytes. This suggests that 
melanocytes' resistance to p53 expression is an intrinsic trait as melanocytes are programmed 
to last for the whole life of the organism, even with the induction of p53 by oxidative stress 
(UV light) of melanin production (Box, N. F et al., 2014). Revealing the mechanisms that 
determine the low mutational rate of p53 in melanoma and wild type p53 inactivation could 
drive new ways to induce p53 reactivation in melanoma treatment (Box, N. F et al., 2014). 
E. Negative Regulation of p53 by MDM2/MDM4 
Known for its ability to negatively regulate the p53 protein is MDM2 (murine double minute 
2, also known as HDM2 in humans) (Kubbutat, M. H et al., 1997) (Bohlman, S., & Manfredi, 
J. J., 2014). Moreover, Mdm2 is considered to be an E3 ubiquitin ligase that binds to p53 
protein to degrade it by ubiquitination (Haupt, Y et al., 1997) (Honda, R et al., 1997) 
(Ponnuswamy, A et al., 2012) (Bohlman, S., & Manfredi, J. J., 2014). At the N-terminus of 
p53, Mdm2 can directly bind, inhibiting the transcriptional activity of p53 for anti-
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proliferative genes (Momand, J et al., 1992) (Bohlman, S., & Manfredi, J. J., 2014). Overall, 
MDM2 can repress the activity of p53 in two significant ways; one is inhibiting the p53 
transactivation domain (Momand, J et al., 1992) (Oliner, J. D et al., 1993) (Shadfan, M et al., 
2012), and another way is ubiquitination of p53, which leads to proteasomal degradation 
(Haupt, Y et al., 1997) (Kubbutat, M. H et al., 1997) (Shadfan, M et al., 2012).  MDM2 is a 
potent inhibitor of p53 and oncogenic when overexpressed. MDM2 inhibition of p53 is 
controlled by a negative feedback loop in which p53 transcriptionally stimulates the 
production of the MDM2 protein, then MDM2 inhibits p53 (Fakharzadeh, S. S et al., 1991) 
(Shadfan, M et al., 2012). This negative feedback loop is important for regulating the activity 
of p53 to prevent the harmful effects of the overactivity of p53. Mice studies have shown that 
knockdown of MDM2 in mice is embryonic lethal. In the absence of MDM2, p53 becomes 
overactive, which will lead to excessive apoptosis and eventually, cell death. In contrast, if 
MDM4 overexpressed, it will inhibit the p53 function of inducing apoptosis, resulting in 
continuous growth of cells and eventually, cancers. Therefore, MDM2 at normal level is 
essential to maintain the p53 function since overexpression of MDM2 leads to 
carcinogenesis, and the knockdown of MDM2 leads to overactivity of p53 (Montes de Oca 
Luna et al., 1995) (Jones, S. N et al., 1995) (Shadfan, M et al., 2012). In addition to its 
interaction with p53, MDM2 is also a key regulator of MDM4 (alternatively termed MDMX 
or HDM4, HDMX in humans). MDM4 (a homolog to MDM2) negatively regulates p53, and 
also MDM4 lacks ubiquitin ligase activity, but still able to bind p53 and suppress its 
transcriptional activity (Shvarts et al., 1996) (Bottger et al., 1999) (Markey, M., & Berberich, 
S. J., 2008). Moreover, the overexpression of MDM4 is found in many cancers like breast 
cancer (Danovi et al., 2004) (Markey, M., & Berberich, S. J., 2008), uterine cancer, gastric 
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cancer, small intestine cancer, colorectal cancer, lung cancer, and skin cancer (reviewed in 
Toledo and Wahl, 2006) (Markey, M., & Berberich, S. J., 2008). MDM4 is encoded on 
chromosome 1q32.1 in the human genome and consists of 11 exons expressed as several 
splice variants. MDM2 and MDM4 share a similar structure that consists of four domains: a 
p53-binding domain at N-terminus, a zinc finger domain, an acidic domain, and a RING 
domain at the c-terminus (Chen, J et al., 2012) (Haupt, S et al., 2019) (Figure 1). The 
significant structural difference is that MDM2 has a nuclear export signal and a nuclear 
localization signal where MDM4 does not (Markey, M., & Berberich, S. J., 2008). 
 
Figure 1. Schematic illustration of the domain structures of p53, MDM2, and MDM4. 
(A) The domain structure of p53 consists of transactivation domain (TAD) at the N-terminus, 
a proline-rich domain (PR), a DNA binding core domain (DBD), an oligomerization domain 
(OD), and regulatory domain (RD) at the C-terminus. (B) MDM2 and MDM4 have related 
structures with a p53 binding domain at the N-terminus, a zinc finger motif, an acidic 
domain, and the RING domain at the C-terminus (the RING domain does not have an active 




  MDM2 and MDM4 can interact with each other and affect each other functionally.  In 
vitro, homodimerization MDM2 with MDM4 can occur via their RING domains (Sharp, D. 
A et al., 1999) (Pei, D., Zhang et al., 2012) Studies have shown that MDM4 stabilizes 
MDM2 by interfering with its self-ubiquitination. Nevertheless, some studies suggest MDM2 
can also ubiquitinate MDM4 and degrade it (Pan, Y., & Chen, J., 2003) (Pei, D., Zhang, et 
al., 2012). Other studies indicate that MDM4 competes with MDM2 for the p53 binding site 
preventing it from degrading p53, leading to the accumulation of p53 (Sharp, D. A et al., 
1999) (Stad, R et al., 2000) (Pei, D., Zhang et al., 2012). In a heteroduplex form, MDM2 and 
MDM4 proteins are predominantly found in cells (Kawai, H et al., 2007) (Pei, D., Zhang et 
al., 2012), implying the heteroduplex form is favored over the homoduplexes form 
(Reviewed in Marine, J. C et al., 2006) (Pei, D., Zhang, et al., 2012). MDM2 and MDM4 are 
both essential for the cell survival, several studies have been performed to determine whether 
MDM2 and MDM4 are required or not because each proteins has different role in the 
regulation of p53, or because both must function as one heterocomplex together (Shadfan, M 
et al., 2012) (Figure 2). MDM2 and MDM4 are overexpressed in many cancers, including 




Figure 2. Two Proposed Models of MDM2 and MDM4 interaction with p53. In the first 
model, both MDM2 and MDM4 are necessary for inhibiting p53 function because both have 
a different mechanism by which it represses p53. While MDM2 is responsible for 
ubiquitination, leading to changes in localization and degradation of p53, MDM4 is required 
for suppressing p53 by inhibiting the transactivation domain (TAD) of p53.  In the other 
model, MDM2 and MDM4 together form complex for inhibiting p53. In this model, MDM2 
and MDM4 are reliant on one another for p53 inhibition. Updated from (Shadfan, M et al., 
2012).  
 
F. MDM4 as a Therapeutic Target in Melanoma 
In the majority of cutaneous melanomas, the p53 pathway is inactivated due to the 
overexpression of MDM4 (Reviewed in Marine & Jochemsen, 2005) (Toledo, F., & Wahl, 
G. M., 2006) (Gembarska, A et al.,2012). MDM4 is considered oncogenic in melanomas and 
other cancers due to its role in inhibiting the p53 pathway (Reviewed in Marine, J et al., 
2006) (AbuHammad, S et al., 2019). Interestingly, MDM4 overexpression is observed in 
roughly 65% of all melanomas (Mrkvová, Z et al., 2019) (Gembarska, A et al.,2012). 
Disrupting the MDM4-p53 interaction inhibits the tumorigenesis of melanoma cells 
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(Gembarska, A et al., 2012). A recent study argues that MDM4 inhibition is a more 
reasonable and less risky strategy than MDM2 inhibition for restoring p53 activity 
(Gembarska, A et al.,2012). Targeting MDM4-p53 interaction may have therapeutics 
potential to enhance BRAF inhibitor therapy. Importantly, targeting MDM4-p53 interaction 
can be an effective treatment in melanoma when resistance to BRAF inhibitors arises (ibid).  
G. Alternative Splicing in Melanoma 
Alternative RNA splicing plays a vital part in controlling protein diversity by skipping 
particular exons and promoting intron retention, leading to the expression of different 
isoforms with premature stop codons (Reviewed in Graveley, B. R., 2001) (Bardot, B., & 
Toledo, F., 2017). Additionally, alternative splicing is a critical process that regulates gene 
expression (Grellscheid, S et al., 2011) (Ge, Y. et al., 2013) (Bardot, B., & Toledo, F., 2017). 
Some previous studies have shown that abnormal splicing promotes cancer (Karni, R et al., 
2007) (Reviewed in Fackenthal, J. D., & Godley, L. A., 2008) (Izaguirre, D. I et al., 2012) 
(Ma, F. C et al., 2019). Moreover, altered splicing may generate oncogenic transcript 
variants. Several studies have identified specific isoforms with clinical utility as that mRNA 
splicing shows prognostic biomarkers in the lung (Li, Y et al., 2017) (Ma, F. C et al., 2019), 
ovarian (Zhu, J., Chen, Z., & Yong, L., 2018) (Ma, F. C et al., 2019), breast (Suo, C et al., 
2015) (Ma, F. C et al., 2019), and brain cancers (Pal, S et al., 2014) (Ma, F. C et al., 2019). 
However, the need for survival analysis of alternative splicing of MDM4 in melanoma is 
urgent since no previous studies have assessed MDM4 isoform levels in melanoma (Ma, F. C 
et al., 2019).   
H. MDM4 Splice Variants  
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Studies conducted on human cancers have shown that the abnormal expression of MDM4 in 
several tumors is associated with WT-p53, suggesting MDM4 may have a vital role in 
regulating the p53 pathway in cancerous cells. The amplification of the MDM4 gene is 
frequent in human cancers (Toledo, F., & Wahl, G. M., 2006) (Mancini, F et al., 2009).  
Besides the full-length of MDM4 (MDM4-FL), at least five shorter forms of MDM4 have 
been observed in 31 cancer cell lines (Ramos, Y. F et al., 2001) (Mancini, F et al., 2009). 
Only one of these forms has been detected in healthy melanocytes, supporting the theory that 
the other MDM4 isoforms occur in tumor cells specifically. Since that time, seven shorter 
MDM4 isoforms have been identified. All of these variants resulted from alternative splicing 
(Figure 3) (Mancini, F et al., 2009).  
The first transcript variant discovered in mice and in human cells was MDM4-S 
(Rallapalli, R et al., 1999) (Mancini, F et al., 2009). Human MDM4-S arises from an internal 
deletion of 68 base pairs in exon 6. This deletion changes the reading frame following codon 
114 and introduces a new termination codon after amino acid 140, resulting in a truncated 
protein that harbors the first 114 amino acids of the MDM4-FL (the whole p53 binding 
domain), so MDM4-S can interact with p53 ( Reviewed in Marine, J. C., & Jochemsen, A. 
G., 2005) (Mancini, F et al., 2009). MDM4-S affinity toward p53 is around 10-fold higher 
than MDM4-FL. As a result, MDM4-S is a more powerful suppressor of the transcriptional 
activity of p53. A nuclear and cytosolic fractions analysis suggests that endogenous MDM4-
S is located inside the nucleus. Interestingly, it has been hypothesized that the transcriptional 
repression of p53 by MDM4-S is the reason for its oncogenic potential (Rallapalli, R et al., 
1999) (Rallapalli, R et al., 2003) (Mancini, F et al., 2009).  
14 
 
MDM4-A has no acidic domain due to the deletion of 225-274 amino acids. As a 
consequence, MDM4-A is suspected to have a strong susceptibility to being degraded by 
MDM2, suggesting the importance of the acidic domain in MDM4-FL stability. Although 
comprehensive studies are needed to elucidate the mechanism that causes MDM4-A 
destabilization, it has been shown that the MDM4 acidic region may mask the MDM2 acidic 
region and repress its ubiquitination activity, particularly toward p53, which also relies on the 
existence of the acidic domain. Therefore, MDM4-A may have oncogenic function by 
degrading MDM2 (de Graaf, P et al., 2003) (Mancini, F et al., 2009).  
The isoform MDM4-G lacks the p53-binding domain due to an in-frame deletion of 
27-124 amino acids. However, MDM4-G lacks the p53-binding domain, but can still inhibit 
p53 activity by stabilizing MDM2 levels, but this inhibition is less pronounced than the 
inhibition by MDM4-FL (Mancini, F et al., 2009).  
            MDM4-211 is an isoform of MDM4 reported in a thyroid tumor cell line which 
results from an aberrant splicing event between the exon two donor site and exon eleven 
acceptor site of the full-length MDM4. This variant harbors the first 26 amino acids and the 
last 138 amino acids of MDM4-FL. Moreover, MDM4-211 lacks the p53 binding domain, so 
it does not bind p53. Instead, MDM4-211 is able to bind MDM2 at the C-terminus and 
maintains MDM2 protein stability by boosting the half-life of the protein. In particular, 
MDM4-211 appears to be capable of inhibiting MDM2 degradation function, prompting 
stabilization of p53 (Giglio, S et al., 2005) (Mancini, F et al., 2009).  
In 2006, Lozano’s group discovered in some human tumor cell lines two splice 
variants of MDM4, named ALT1 and ALT2 (Chandler, D. S et al., 2006) (Mancini, F et al., 
2009). Both ALT1 and ALT2 derive from a splicing event, but in ALT1, the event takes 
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place between exon five and exon ten wherein ALT2, it happens between exon three and 
exon ten. ALT1 maintains the p53 binding domain, so presumably it can inhibit the p53 
function. In contrast, ALT2 lacks the p53 binding domain and maintains the COOH-terminal 
RING finger domain. MDM4-ALT2 may bind MDM2 or MDM4-FL and modulate their role. 
An analogous isoform to MDM4-ALT2 that has been identified as MDM2-ALT2. (Chandler, 
D. S et al., 2006) (Mancini, F et al., 2009). No protein product has been detected for ALT1 or 
ALT2. Responding to DNA damage agents cisplatin and doxorubicin, a study revealed that 
MDM4-FL mRNA decreased in vivo and in vitro. Presumably, this decrease was not a result 
of changes in promoter activity but was corresponding with an increase in the splice variant 
ALT2. ALT1 showed no change in response to DNA damage (Reviewed in Markey., 2011).   
No study has thus far determined what actual splice variants of MDM4 are expressed 
in melanoma. Because different variants contain different exons, splicing of MDM4 in 
melanoma may be important in designing molecules targeted to the MDM4 protein. 
Interestingly, we found that MDM4-A is commonly expressed in melanoma cases and has 




Figure 3. Schematic representation of MDM4 mRNA organization in exons (according 
to the GeneBank NM 002393). (A) paralleled the structure of the MDM4 protein regions. 
Exons are numbered consecutively and boxed in approximate scale (B) MDM4 alternative 
transcripts.         represents the forward primer used in these studies. The reverse primer is 
represented as       . Dashed lines span novel exon junctions. RT-PCR amplicon sizes are 
indicated at right. Primers not drawn to scale. Adapted from (MDM4 (MDMX) and its 










II. MATERIAL AND METHODS 
 
1. Collecting FFPE Samples. 
 
A total of 40 formalin-fixed, paraffin-embedded (FFPE) specimens (30 malignant 
melanomas and 10 benign melanocytic nevi) were collected from American 
Dermatopathology Laboratory. For melanoma samples (case 1 to 30), clinical diagnostic 
details concerning melanoma patients were provided by American Dermatopathology 
Laboratory, including the patient's age at diagnosis, the patient's sex, the biopsy site, Breslow 
thickness, the tumor staging, nevus association, and the Castle Class (Table 1). For the 
benign nevi, clinical information about the patients was obtained from American 
Dermatopathology Laboratory, including the patient's age at diagnosis, patient's gender, and 
biopsy site (Table 2). 
Table 1: Melanoma samples. Cases listed with patients’ age, gender, biopsy site, size, 
staging, associated nevus, and Castle Class. Castle's DecisionDx-Melanoma test is a 31-gene 
expression profile that determines a patient's risk for metastatic disease using tissue from the 
primary melanoma. The tool classifies patients as having a tumor with low or high risk for 
developing metastasis within five years of diagnosis (Castle Bioscience). The TNM is a 
universally accepted standard for classifying the degree of cancer spreading (NIH). Breslow 
thickness is a prognostic factor in melanoma used to determine the depth of tumor invasion 
(Breslow Alexander., 1970). 
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Cases Patient Age Patient Sex Biopsy Site Breslow Thickness TNM Staging Assoc. Nevus (Y or N) Castle Class #
Case 1 49 M Right Upper Back PS 0.5mm pT1a, Nx, Mx; STAGE IA Y 1A
Case 2 55 M Right Back 1.5mm pT2a, Nx, Mx; STAGE IB N 1B
Case 3 67 M Left Ear 1.6mm pT2a, Nx, Mx; STAGE IB N 1A
Case 4 50 M Left Medial Calf 2.5mm pT3b, Nx, Mx; STAGE IIB N 2B
Case 5 53 M Right Superior Upper Back 0.4mm  pT1a, Nx, Mx; STAGE IA N 1A
Case 6 33 F Left Posterior Shoulder 0.4mm  pT1a, Nx, Mx; STAGE IA Y 1A
Case 7 53 M Right Inner Thigh 0.8mm pT1b, Nx, Mx; STAGE IB N 1B
Case 8 68 M Nose 0.5mm pT1b, Nx, Mx; STAGE IB N 2A
Case 9 64 M Right Calf 0.6mm pT1b, Nx, Mx; STAG IB N 1B
Case 10 74 M Left Forearm Proximal 2.1mm pT3b, Nx, Mx; STAGE IIB N 2B
Case 11 70 M Left Upper Arm 0.3mm pT1a, Nx, Mx; STAGE IA N 1A
Case 12 71 M Right Posterior Shoulder 0.3mm  pT1A, Nx, Mx; STAGE IA N 1A
Case 13 71 M Left Forearm 1.5mm  pT2a, Nx, Mx; STAGE IB N 2B
Case 14 29 F Right Upper Helix 0.5mm pT1a, Nx, Mx; STAGE IA N 1A
Case 15 39 M Right Anterior Deltoid 1.1mm pT2a, Nx, Mx; STAGE IB Y 1A
Case 16 58 F Left Upper Arm 0.9mm pT1b, Nx, Mx; CLINICAL STAGE IB N 1A
Case 17 63 F Left Upper Arm 0.9mm pT1b, Nx, Mx; STAGE IB Y 1A
Case 18 83 M Scalp 1.7mm pT2a, Nx, Mx; STAGE IB N 2A
Case 19 73 M Vertex 0.5mm pT1a, Nx, Mx; STAGE IA N 1A
Case 20 67 M Right Arm 0.4mm pT1a, Nx, Mx; STAGE IA Y 1A
Case 21 43 F Right Abdomen 0.4mm pT1a, Nx, Mx; STAGE IA Y 1A
Case 22 61 F Right Thigh 0.9mm pT1b, Nx, Mx; STAGE IB Y 1A
Case 23 68 F Left Ant. Prox. Thigh 0.7mm pT1a, Nx, Mx; STAGE IA N 1A
Case 24 73 F Right Upper Post. Arm 2.5mm pT3b, Nx, Mx; STAGE IIB N 2B
Case 25 71 F Left Post. Shoulder 0.4mm pT1a, Nx, Mx; STAGE IA N 1A
Case 26 79 M Right Post. Calf 1.2mm pT2b, Nx, Mx; STAGE IIA N 2A
Case 27 57 F Left Post. Deltoid 0.5mm  pT1a, Nx, Mx; Stage IA N 1A
Case 28 47 F Top Scalp 4.1mm pT4b, Nx, Mx; Stage IIC N 2B
Case 29 70 M Right Lower Leg 0.8mm pT1b, Nx, Mx; STAGE IB N 1A
Case 30 77 M Back of Neck 5.0mm pT4b, Nx, Mx; STAGE IIC N 2B  
 





Sex Bioposy Site 
Case 31 14 F Right T4
Case 32 32 F Left temple
Case 33 34 F Right antecubital
Case 34 60 F Left mid. Lat. Low. Extremity
Case 35 2 M Might medial forearm
Case 36 49 F Left medial thigh
Case 37 41 F Right mid. Inframammary fold
Case 38 54 F right alar crease
Case 39 15 F right dorsal forearm
Case 40 25 F Right posterior thigh
 
2. Primer Design for MDM4 splice variants 
The sequence of MDM4 isoforms obtained from the Ensembl genome browser was used for 
primer design. The transcript sequences were as follows (Forward): MDM4-Fl, 5′- 
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AGATGCTGCTCAGACTCTCG -3′. MDM4-211, 5′- CTCCTGGACAAATCAATCAGGAAA -
3′. MDM4-Alt1, 5′- CAGGTGCGCAAGGTGAAATG -3′. MDM4-Alt2, 5′- 
ACTGTTAAAGAGGTGATTGAAGTGG -3′. MDM4-A, 5′- CACACTGCCTACCTCAGAGC -
3′. MDM4-G, 5′- CCTGGACAAATCAATCAGGATCAC -3′. MDM4-S, 5′- 
CAGCAGGTGCGCAAGGTGAA -3′. B-Actin (negative control), 5′- 
TTCCTATGTGGGCGACGAG -3′. The reverse primers were as the following: MDM4-Fl, 5′- 
TCAGGATGTGGGTACTGCCA -3′. MDM4-211, 5′- TGATCCCTGCAACTCAGTGG -3′. 
MDM4-Alt1, 5′- ACTACAGGTGATTGAAGTGGGA -3′. MDM4-Alt2, 5′- 
TGATCCCTGCAACTCAGTGG -3′. MDM4-A, 5′- GACAAATCAGGTGATTGAAGTGGG -
3′. MDM4-G, 5′- TATCCCCACACTGCCTACCT -3′. MDM4-S, 5′- 
CACTGCTACTACAGCAAAGTG -3′. B-Actin, 5′- CGTGTGGCTCCCGAGGA -3′.  
3. RNA Extraction & Purification from FFPE tissues 
RNA was extracted from FFPE specimens using the truXTRAC FFPE RNA Kit (Covaris, 
Woburn, MA) and a M220 System and following the manufacturer's protocol. All 40 samples 
were treated with RNA Lysis, RNA Wash, RNA Elution, B1 Buffer, DNase Buffer, DNase I, 
PK Solution, MnCl2 Solution, Ethanol (>96%), and nuclease free water. All samples were 
incubated in a dry heat block for two phases, wherein the first phase (proteinase K digestion 
at 56°C) samples were incubated for 15 minutes, the second phase (crosslink reversal at 
80°C) samples were heated for 60 minutes. All samples were centrifuged. Once the RNA 
purification process was completed, sample RNA was quantified by Nanodrop (Table 3) and 
stored immediately at -80°C.  
Table 3: The amount of RNA in each sample after RNA extraction and purification 
process. RT stands for reverse transcriptase, an enzyme that generates complementary strand 
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(cDNA) from RNA. The first two cases were transcribed with Oligod(T) primers and the rest 
with Random Hexamer.  
 
4. cDNA Synthesis and RT-PCR 
500 ng of RNA was reverse transcribed with 50 ng/µl random hexamers or 500 ng/µl Oligo 
d(T) primer using The SuperScript IV CellsDirect cDNA Synthesis Kit (Applied 
Biosystems). The first two samples were transcribed with 50 uM Oligo d(T), but the rest 
were transcribed with 50 ng/µl random hexamers. We switched from Oligo d(T) to random 
hexamers because Oligo d(T) highly specific and cDNA synthesis has to start from the 3′ end 
where to random hexamers is more effective reliable for our FFPE samples since its capable 
to prime the fragmented mRNA. However, the reverse transcription of the first two samples 
worked successfully and showed that we have long mRNA from our FFPE samples. For the 
RT-products, each product was prepared in accordance to Promega’s instructions for a 25 µ/l 
reaction volume [12.5 µl GoTaq® Green Master Mix, 1 µl upstream primer, 1 µl 
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downstream primer, 2 µl DNA template, and 8.5 µl Nuclease-Free water] and PCR was 
performed for 2 minutes at 95°C (the initial denaturation); 30 sec at 95°C; 30 sec at 55°C; 30 
sec at 73°C; 5 minutes at 73°C (a final extension) (Applied Biosystems). Then, RT- products 
were placed on a 2% agarose TBE gel, 2 µl of SYBR safe stain was added, 5 µl of 50bp 
ladder (Manufacturer, City) was loaded, gels were run on 100 V constant for approximately 
60 minutes. Gels imaged on Amersham™ Imager 600 (Manufacturer, City).  
5. MDM4 Isoform Analysis  
Gene mutation frequency in melanoma obtained from the data set “skin cutaneous 
melanoma” (SKCM-US), a 466 subject study of melanoma patients in the United States 
(Akbani et al., 2015) and analyzed using the International Cancer Genome Consortium data 
portal (Lawrence et al., 2013, p. 217). The results presented here are based upon data 
obtained from the TCGA Research Network: https://www.cancer.gov/tcga. TCGA copy 
number data for SKCM were analyzed using Oncomine (Rhodes, 2020). TCGA survival data 
for SKCM were analyzed using OncoLnc (Anaya, 2016). Isoform-specific expression data 
for MDM4 in normal skin were analyzed in Genotype-Tissue Expression (GTEx) data portal. 
The data used for the analyses detailed in this manuscript were obtained from the GTEx 
Portal and dbGaP accession number phs000424.v8.p2 on 5/29/2020.  For melanoma, 
isoform-specific expression data were obtained from the Patient Derived Model Database 
(PDMDB). TPM isoform data were filtered for disease body location “skin” plus CTEP SDC 
description “melanoma”.  UCSC Genome Browser isoform identifiers were matched to 
transcripts modeled in Ensembl in order to compare with GTEx data. Kaplan-Meier analysis 
of TCGA data for specific isoforms of MDM4 was performed using Psichomics (Saraiva-
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Agostinho N et al., 2019) in Bioconductor. TCGA exon expression and survival data were 
interpreted commensurate with the inclusion of MDM4 exon 9 and the skipping of exon 9. 
6. Statistical Analysis 
An unpaired t-test was performed to assess the statistical significance in comparing Castle 
Class versus isoform presence in the 30 melanoma specimens. P (two-tailed) values of less 






















i. Mutational gene analysis indicates that most melanomas have intact p53 
Mutations in the p53 protein are frequent genetic alterations seen in human tumors (Rady et 
al., 1992) (Greenblatt et al., 1994) (Hollstein et al., 1994) (Hollstein et al., 1996) (Hainaut et 
al., 1997) (Zerp, S et al., 1999). The p53 protein is associated with several biological 
processes that control the proliferation and survival of cells. Amplifications in the p53 
protein frequently occur in skin cancers (Brash et al., 1991) (Rady et al., 1992) (Campbell et 
al., 1993) (Moles et al., 1993) (Zeigler et al., 1993) (Zerp, S et al., 1999). Several data have 
revealed that genetic alterations in the p53 gene happen onset of carcinogenesis.  Moreover, 
studies conducted in animal models showed frequent mutations of the p53 gene in animal 
tumors generated by UV-B treatment (Kanjilal et al., 1993) (van Kranen et al., 1995) (Zerp, S 
et al., 1999). Some data suggest that the occurrence of p53 mutations in primary melanomas 
is more frequent than in metastases (Zerp, S et al., 1999). Several genetic mutations are 
involved in tumorigenesis of melanoma, and one way to understand the genetics of 
melanoma is by determining the frequency of genes mutated in it. Therefore, we collected 
data from the TCGA project to investigate the frequency of genes mutated in melanoma. 
Surprisingly, we found that around 90% of melanoma subjects possess an intact p53 gene 
and 50% of melanoma subjects have BRAF mutation (Figure 4). p53 mutations were more 
commonly found in BRAF tumors than in Triple-WT, in which MDM2 amplification was 
more common (TCGA., 2015). Next, we wanted to compare the amplification of both 




Figure 4. Most melanomas have an intact p53 gene. Tumors from 466 melanoma subjects 
in the United States were tested for simple somatic mutations as part of the TCGA study 
SKCM-US (Akbani et al., 2015). Genes were ranked by the frequency of mutation. The top 
20 results are shown.   
 
ii. MDM4 is more frequently amplified in melanoma than MDM2 
MDM2 is commonly overexpressed in several cancers like gliomas, melanomas, sarcomas, 
hematological malignancies, and carcinomas. Similarly, MDM4 is also largely overexpressed 
in many human cancers (Li, Q., & Lozano, G., 2013). The amplification and the 
overexpression of MDM4 were observed in different cancers such as melanoma, glioma, 
squamous carcinoma, soft tissue sarcoma, retinoblastoma, and breast cancer (Li, Q., & 
Lozano, G., 2013). We wanted to compare the amplification of MDM2 to the amplification 
of MDM4 in melanoma. In that, we obtained copy number variation data again from TCGA 
for the genes MDM2 and MDM4. The blood samples are normal karyotypes for patients, 
which were compared to melanomas. Figure.5 shows the relative change in copy number 
versus normal. Interestingly, MDM2 copy number in melanoma was very similar to copy 
number in blood, suggesting that MDM2 is poorly amplified in melanoma (Figure 5A). 
Conversely, the copy number of MDM4 in melanoma was higher, indicating that MDM4 is 
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amplified in melanoma (Figure 5B). This data suggests that MDM4 amplification is more 
frequent than MDM2 amplification in melanoma and emphasizes on the importance of 
MDM4 in melanoma. This brings up the question if the amplification of MDM4 have clinical 
significance or not. 
 
Figure 5. MDM4 is frequently amplified in melanoma, in contrast with MDM2. Skin 
cutaneous melanoma data from TCGA with copy number data available for tumor and 
matched normal tissue (blood) were analyzed for amplification or deletion of the genes 
MDM2 (a) and MDM4 (b). Log2 copy number is normalized to the copy number in blood. 
 
iii. The expression of MDM4 and survival in melanoma 
To investigate whether or not MDM4 expression contributes to the poor survival in 
melanoma cells, we collected TCGA survival data for melanoma and performed Kaplan-
Meier analysis to determine the impact of MDM4 expression in melanoma. The expression 
of MDM4 separated into two groups: red group (the upper quartile of MDM4 expression) 
and blue group (the lowest quartile of MDM4 expression), as shown the Figure 6 below. 





Figure 6. MDM4 expression does not significantly correlate with patient survival. 
TCGA survival data for skin cutaneous melanoma were separated by expression of MDM4.  
The “High” group (red) had expression of MDM4 in the top 25% of available subjects. 
“Low” (blue) subjects were in the bottom 25% of expression for MDM4. N for each group is 
114 subjects.  Kaplan-Meier analysis indicates not significant difference in, log rank p-value 
= 0.247.  
 
iv. The expression of MDM4 splice variants in sun exposed skin is similar in 
non-sun exposed skin. 
 
Before looking into our melanoma and nevi samples, we wanted to look into normal skin 
data to compare later the results of normal skin to cancerous skin. We used publicly available 
GTEx portal data to compare the expression of the MDM4 isoforms between sun-exposed 
and not sun-exposed. Interestingly, expression of all MDM4 isoforms was very similar 
between sun-exposed and non-sun exposed skin. MDM4-A was absent in both exposed and 





Figure 7. MDM4 isoform expression in normal skin. Non-sun exposed (suprapubic) 
skin specimen data from 604 subjects and sun-exposed (lower leg) skin specimens from 
701 subjects were analyzed in the GTEx data portal. Normalized reads x100 for each 
indicated isoform of MDM4 are displayed. Isoforms are labeled using their common 
names. The Transcript Support Level (TSL) is designed to highlight the well-supported 
and poorly supported transcript patterns. Ensembl transcript evidence level 1 (TSL1) 
transcripts are in bold. *This Ensembl transcript shares a name with the transcript 
commonly called MDM4-211.  **Two transcripts encode MDM4-S.  
 
v. Comparing Castle Class to isoforms presence statistically showed MDM4-S 
is significant in melanoma samples  
 
We collected a total of 40 samples (30 melanoma + 10 nevi). In melanoma specimens, 18 out 
of 30 were classified as 1A, 3 patients’ samples were on level 1B, 4 cases diagnosed as 2A, 
and lastly, the remaining 6 were classified as 2B. MDM4-A was the most common isoform 
to be expressed in patients that were diagnosed as 1A Castle Class as we compared the 
isoform presence to the castle class. We performed an unpaired t-test to assess the statistical 
significance of MDM4 isoforms, and we found MDM4-S was significantly the highest 




Figure 8. Statistical significance analysis of MDM4 isoforms in melanoma specimens. 
Castle Class did not vary significantly by MDM4 isoform expression (p>0.05). MDM4-211 
was not detected in our samples. 
 
vi. MDM4-A is the most common alternative transcript expressed in 
melanoma samples 
Previous studies have shown that amplification and overexpression of MDM4 is typically 
observed with suppression of the p53 pathway in human tumors (Riemenschneider, M. J et 
al., 2003) (Wasylishen, A. R et al., 2016) (Pant, V et al., 2017). Additionally, some studies 
have pointed to the MDM4 spliced variant expression in several cancers, especially in 
melanoma (Bartel, F et al., 2005; Mancini, F et al., 2009; as cited in Pant, V et al., 2017), 
where MDM4 observed a high level of expression in about 65% of cases (Gembarska, A et 
al.,2012). However, no work thus far has been conducted on what spliced variants of MDM4 
are expressed in melanomas. Therefore, we sought to determine which variants are expressed 
in our FFPE samples, so we performed RT-PCR for each sample. The full-length MDM4 
mRNA (MDM4-FL) was expressed in about 53% of melanoma samples and 40% of normal 
skin (nevi or benign). The alternative transcripts MDM4-G and MDM4-S were similarly 
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expressed but not signifcantly more in the nevi specimens than in malignant specimens. By 
contrast, the splice variant MDM4-Alt2 was frequently expressed in melanoma specimens 
and less so in nevi samples. The expression of the isoform MDM4-211 was not detected in 
either our melanomas or benign specimens. Moreover, the alternative transcript MDM4-Alt1 
was expressed in only one sample of benign melanocytic nevus. MDM4-A was the most 
common transcript expressed in malignant melanoma. All the results of the FFPE samples 
are shown in the below Table 4. 
Table 4: Summary of RT-PCR results in melanoma and nevi samples. The First 30 cases 
are for melanoma patients and cases from 31 through 40 are nevi. (-) means no expression 
was detected. (+) means expression was detected. The details for each case were provided in 
Table 1 and Table 2.  
Cases  MDM4-G  MDM4-A MDM4-S XAlt1 XAlt2 MDM4 -211 FL 
Case 1 + + + - + - + 
Case 2 - + + - + - + 
Case 3 + + + - + - + 
Case 4 + + + - + - + 
Case 5 - + + - + - + 
Case 6 - - + - + - + 
Case 7 - + + - + - + 
Case 8 + + + - + - + 
Case 9 - + + - + - + 
Case 10 - + + - + - + 
Case 11 - + + - + - + 
Case 12 + + + - + - + 
Case 13 + + + - + - + 
Case 14 - + + - + - + 
Case 15 - + + - + - + 
Case 16 - + - - - - - 
Case 17 - + + - + - + 
Case 18 - + + - + - - 
Case 19 + + + - - - - 
Case 20 + + + - + - - 
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Case 21 - + + - - - - 
Case 22 - + + - - - - 
Case 23 + + + - - - - 
Case 24 + + + - - - - 
Case 25 - - - - + - - 
Case 26 - + + - - - - 
Case 27 - + + - - - - 
Case 28 - + + - - - - 
Case 29 - + - - - - - 
Case 30 - + + - - - - 
Case 31 + + + - - - - 
Case 32 - - + - + - - 
Case 33 + + + - + - + 
Case 34 + + + - + - + 
Case 35 + + + - - - + 
Case 36 + + + - + - + 
Case 37 + + + - + - - 
Case 38 - + - - - - - 
Case 39 + + + + - - - 
Case 40 - + + - + - - 
 
vii. Isoform specific expression analysis showed consistent expression of the 
alternative transcript MDM4-A. 
The Patient-Derived Model Database (PDMDB) is a database containing expression data for 
various tumor types, including melanoma. Data obtained from PDMDB were analyzed and 
found MDM4-211 and MDM4-A in addition to the full-length MDM4 expressed in 
melanoma patients. The MDM4-FL was expressed in 43% of melanoma patients. MDM4-
211 was expressed in about 0.0046% of melanoma patients, which correlates with our FFPE 
biopsy results. MDM4-A was the most common isoform expressed by in 57% of melanomas 
(Figure 9A). In contrast, the full length MDM2 (isoform MDM2-A here) was the almost 
exclusively detected in the PDMDB database (Figure 9B). Both PDMDB data and FFPE 






Figure 9. MDM4 isoform expression in melanocytic lesions is different from normal 
skin. Isoform-specific expression data were compared for 120 patient-derived xenografts. 
The percentage of total MDM4 transcripts represented by each isoform is indicated.  (a) 
Expression of the alternative transcript MDM4-A is significantly more common than 
expression of the full length MDM4 transcript in these specimens (students t-test p-value 
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= 1.386 x10-13). (b) In contrast, MDM2 expression is almost entirely the full-length 
transcript designated MDM2-A. (c) Analysis of 30 clinical melanoma specimens and 10 
melanocytic benign nevi by isoform-specific RT-PCR.  
viii. MDM4-A isoform correlates with poor survival in melanoma 
Here, we wanted to test whether MDM4-A correlates to melanoma survival. We used TCGA 
samples with exon expression data and survival data to investigate the correlation of MDM4-
A with survivorship in melanoma. Our analysis was based on including MDM4 exon 9 and 
skipping of exon 9 (MDM4-A skips exon 9). Significantly, the survival of cases where 
MDM4-A represented ≥80% of transcripts had notably higher survival than cases where 
≥80% of transcripts lacked exon 9, suggesting that MDM4-A correlates with reduced 
survivorship in melanoma (Figure 10).  
 
Figure 10. MDM4-A isoform correlates with poor survival. TCGA samples with exon 
expression data and survival data were analyzed based on inclusion of MDM4 exon 9.  
Skipping of exon 9 indicates MDM4-A.  The survival of subjects with an exon 9 percent 
spliced in (PSI) greater than 0.8 (indicating inclusion of exon 9 seen in ≥80% of transcripts) 
had significantly higher survival than subjects where ≥80% of transcripts skipped exon 9 




IV. DISCUSSION  
Many environmental and genetic factors influence the tumorigenesis of melanoma, including 
sun exposure, which is the most significant environmental risk factor for melanoma 
development because it damages the DNA (Landi, M. T et al., 2020). The p53 pathway 
becomes activated in response to DNA damage (Luo et al. 2004) (Williams, A. B., & 
Schumacher, B., 2016). Other risk factors that give rise to melanoma development are family 
history, skin color, and many freckles and moles on the skin (Landi, M. T et al., 2020). 
Melanoma development and progression are recognized by chromosomal deletions, 
proliferation, and gene alterations (Chin et al., 2006) (Staibano, S et al., 2011). Studies on 
gene expression of melanomas showed that melanomas have many genetic mutations. 
(Fecher et al., 2007) (Ryu et al., 2007) (Staibano, S et al., 2011), including BRAF mutations, 
KIT mutations, and Plexin B1 mutations (Staibano, S et al., 2011). In addition to these 
mutations, the p53 pathway inactivation found to be a common theme in melanoma, 
considering 90% of melanoma cases retain WT p53 (Hocker, T., & Tsao, H. 2007) (Box, N. 
F et al., 2014). The p53 pathway is negatively regulated by MDM2 and its homolog MDM4 
in many cancers, including melanoma (Reviewed in Wade, M et al., 2013) (Mrkvová, Z et 
al., 2019). Our data showed that most melanoma patients have a high percentage of intact 
p53, as shown in (Figure 4).  
 A study reported that MDM4 is overexpressed in about 65% of melanoma cases 
(Gembarska, A et al.,2012), pointing to the importance of studying MDM4 overexpression in 
melanoma. Additionally, MDM4 can suppress the p53 activity solely by indirect negative 
regulation or by heterodimerization with MDM2. However, we found that the MDM4 gene is 
more amplified than MDM2 in melanoma (Figure 5). Our analysis of MDM4 isoforms in 
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normal skin showed no MDM4-A expression (Figure 7). However, and to date, no previous 
studies have been performed on determining which isoforms are expressed in melanoma 
cells.  
 We found that our melanoma and nevi specimens appear remarkably similar in their 
MDM4 isoforms profiles. Two of the alternative transcripts of MDM4 were expressed 
frequently in 90% of our samples (Table 4). MDM4-ALT1 and MDM4-211 transcripts were 
not seen in melanoma cases. Importantly, among all MDM4 isoforms, MDM4-A was the 
most common isoform expressed in our melanoma samples (Figure 9). We performed 
analyses that suggested that MDM4-A was linked to poor survival of melanoma (Figure 10), 
even though total MDM4 expression was not (Figure 6). Together, our results suggest a 
model where aberrant splicing of MDM4 occurs early in carcinogenesis, MDM4 is more 
commonly amplified than its homolog MDM2, that splicing changes of MDM4 are more 
observed in early stages than MDM2 splicing, and that supports the likelihood that MDM4-A 
is an oncogenic variant that promotes oncogenesis (Figure 11).  
  It is interesting that the unexpressed transcripts in melanoma samples, Alt1 and 211, 
have some of the least evidence for their role in cancer. Currently, ALT1, in response to 
DNA damage, might limit the activity of p53 (Mancini, F et al., 2009). MDM4-211 is linked 
to cancer formation in the presence of p53 and MDM2 (Reviewed in Markey M. P., 2011). It 
is more important to note that our results are based on qualitative analysis (what is isoform 
expressed) but not quantitative analysis (how much is expressed). Although we attempted 
quantitative PCR analysis on one sample, we found the quantitative approach using FFPE 
samples to be noisy. Therefore, it may be that some of these variants are expressed more 
highly than others, which is suggested by MDM4-G consistently giving a faint band. The 
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expression of MDM-G and MDM4-Alt2 is particularly interesting because these two lack the 
full p53 domain. The first two samples, primed with oligo-d(T) primers, produced RT-PCR 
results despite the primers binding far upstream of the 3’ poly-A tail.  This suggests a 
minimum length of approximately 10kb that must be present in the purified mRNA. This 
raises the possibility of using long-read sequencing (such as Oxford Nanopore sequencing) to 
quantify specific transcripts.  This would also have the advantage of identifying novel 
transcripts not previously reported. This remains an important future direction. 
 The value of this study is to highlight the importance of isoforms expression on 
melanoma to improve the treatment of melanoma. The drug vemurafenib has been used to 
cure metastatic melanoma and showed some success in curing melanoma. However, this drug 
only functions effectively in patients who have BRAF mutations (Gembarska, A et al.,2012). 
Recently, some melanoma patients manifested resistance to vemurafenib, highlighting the 
urgent need for new strategies to treat melanoma (Gembarska, A et al.,2012). Our data 
suggest that MDM4-A may correlate with the oncogenesis of melanoma, and considering 
MDM4-A as a therapeutic target in melanoma could drive to positive clinical outcomes 
(Figure 11). Further study is needed to determine how highly this isoform is expressed in 
melanoma cells compared to normal skin and precancerous lesions.    
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Figure 11. Model of Carcinogenesis of melanoma with timeline of MDM2/4/p53 
changes. Acral melanoma has some initiating event besides UV light. Throughout 
progression from normal skin to metastatic disease, most cases retain wild type p53 and 
demonstrate normal splicing and normal copy numbers of MDM2. In contrast, changes in 
MDM4 splicing are already in place in melanocytic nevi.  MDM4 tends to be amplified in 
melanomas, and the profile of mRNA isoforms expressed is different from normal skin. 












V. FUTURE DIRECTIONS 
The project MDM4 alternative splicing may need an increase in the number of specimens, 
especially to compare the expression of MDM4-A in melanoma samples to nevi samples. 
Since we did not detect the presence of MDM4-211, it would be suited to have a positive 
control for it. Also, a survival analysis of MDM4-G is warranted because there is some 
apparent difference in its presence between the melanoma and nevi specimens. Other MDM4 
isoforms such as MDM4-B and MDM4-C can be tested for presence in melanoma and nevi 
specimens. Additionally, we will use expression and mutation data of genes in the MDM4 
regulatory axis to determine which mechanisms control p53 activity in melanoma. Exon 
expression and splice junction data could be used to predict the function of observed MDM4 
transcript variants and identify novel transcripts. Direct cDNA sequencing analysis could be 
performed with long-read sequencing and analyzed with tools such as TALON to annotate 
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